Browse IFNG

Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00714 Interferon gamma
Function

Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0000060 protein import into nucleus, translocation
GO:0001508 action potential
GO:0001562 response to protozoan
GO:0001655 urogenital system development
GO:0001667 ameboidal-type cell migration
GO:0001776 leukocyte homeostasis
GO:0001780 neutrophil homeostasis
GO:0001781 neutrophil apoptotic process
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001822 kidney development
GO:0001889 liver development
GO:0001906 cell killing
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002026 regulation of the force of heart contraction
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002262 myeloid cell homeostasis
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002298 CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response
GO:0002302 CD8-positive, alpha-beta T cell differentiation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002361 CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002573 myeloid leukocyte differentiation
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006066 alcohol metabolic process
GO:0006310 DNA recombination
GO:0006509 membrane protein ectodomain proteolysis
GO:0006606 protein import into nucleus
GO:0006694 steroid biosynthetic process
GO:0006766 vitamin metabolic process
GO:0006775 fat-soluble vitamin metabolic process
GO:0006809 nitric oxide biosynthetic process
GO:0006887 exocytosis
GO:0006913 nucleocytoplasmic transport
GO:0006914 autophagy
GO:0006925 inflammatory cell apoptotic process
GO:0006959 humoral immune response
GO:0006986 response to unfolded protein
GO:0007009 plasma membrane organization
GO:0007050 cell cycle arrest
GO:0007159 leukocyte cell-cell adhesion
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0007271 synaptic transmission, cholinergic
GO:0007272 ensheathment of neurons
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0008202 steroid metabolic process
GO:0008366 axon ensheathment
GO:0009110 vitamin biosynthetic process
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009914 hormone transport
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010657 muscle cell apoptotic process
GO:0010660 regulation of muscle cell apoptotic process
GO:0010661 positive regulation of muscle cell apoptotic process
GO:0010720 positive regulation of cell development
GO:0010817 regulation of hormone levels
GO:0010893 positive regulation of steroid biosynthetic process
GO:0010921 regulation of phosphatase activity
GO:0010922 positive regulation of phosphatase activity
GO:0014009 glial cell proliferation
GO:0014013 regulation of gliogenesis
GO:0015833 peptide transport
GO:0016064 immunoglobulin mediated immune response
GO:0016311 dephosphorylation
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0017038 protein import
GO:0017157 regulation of exocytosis
GO:0018105 peptidyl-serine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0019226 transmission of nerve impulse
GO:0019228 neuronal action potential
GO:0019724 B cell mediated immunity
GO:0019882 antigen processing and presentation
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022612 gland morphogenesis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030316 osteoclast differentiation
GO:0030335 positive regulation of cell migration
GO:0030388 fructose 1,6-bisphosphate metabolic process
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0030656 regulation of vitamin metabolic process
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031640 killing of cells of other organism
GO:0031641 regulation of myelination
GO:0031642 negative regulation of myelination
GO:0031644 regulation of neurological system process
GO:0031645 negative regulation of neurological system process
GO:0032113 regulation of carbohydrate phosphatase activity
GO:0032222 regulation of synaptic transmission, cholinergic
GO:0032224 positive regulation of synaptic transmission, cholinergic
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032615 interleukin-12 production
GO:0032620 interleukin-17 production
GO:0032627 interleukin-23 production
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032655 regulation of interleukin-12 production
GO:0032660 regulation of interleukin-17 production
GO:0032667 regulation of interleukin-23 production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032700 negative regulation of interleukin-17 production
GO:0032722 positive regulation of chemokine production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032747 positive regulation of interleukin-23 production
GO:0032755 positive regulation of interleukin-6 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032768 regulation of monooxygenase activity
GO:0032770 positive regulation of monooxygenase activity
GO:0032829 regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
GO:0032831 positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
GO:0032832 regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response
GO:0032834 positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response
GO:0032835 glomerulus development
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033002 muscle cell proliferation
GO:0033028 myeloid cell apoptotic process
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033139 regulation of peptidyl-serine phosphorylation of STAT protein
GO:0033141 positive regulation of peptidyl-serine phosphorylation of STAT protein
GO:0033619 membrane protein proteolysis
GO:0034341 response to interferon-gamma
GO:0034390 smooth muscle cell apoptotic process
GO:0034391 regulation of smooth muscle cell apoptotic process
GO:0034393 positive regulation of smooth muscle cell apoptotic process
GO:0034504 protein localization to nucleus
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035303 regulation of dephosphorylation
GO:0035306 positive regulation of dephosphorylation
GO:0035637 multicellular organismal signaling
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035821 modification of morphology or physiology of other organism
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036037 CD8-positive, alpha-beta T cell activation
GO:0040017 positive regulation of locomotion
GO:0042033 chemokine biosynthetic process
GO:0042035 regulation of cytokine biosynthetic process
GO:0042063 gliogenesis
GO:0042089 cytokine biosynthetic process
GO:0042090 interleukin-12 biosynthetic process
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0042176 regulation of protein catabolic process
GO:0042226 interleukin-6 biosynthetic process
GO:0042359 vitamin D metabolic process
GO:0042362 fat-soluble vitamin biosynthetic process
GO:0042368 vitamin D biosynthetic process
GO:0042391 regulation of membrane potential
GO:0042493 response to drug
GO:0042501 serine phosphorylation of STAT protein
GO:0042508 tyrosine phosphorylation of Stat1 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042510 regulation of tyrosine phosphorylation of Stat1 protein
GO:0042511 positive regulation of tyrosine phosphorylation of Stat1 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042552 myelination
GO:0042742 defense response to bacterium
GO:0042832 defense response to protozoan
GO:0042886 amide transport
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043374 CD8-positive, alpha-beta T cell differentiation
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044057 regulation of system process
GO:0044110 growth involved in symbiotic interaction
GO:0044116 growth of symbiont involved in interaction with host
GO:0044117 growth of symbiont in host
GO:0044126 regulation of growth of symbiont in host
GO:0044130 negative regulation of growth of symbiont in host
GO:0044144 modulation of growth of symbiont involved in interaction with host
GO:0044146 negative regulation of growth of symbiont involved in interaction with host
GO:0044283 small molecule biosynthetic process
GO:0044364 disruption of cells of other organism
GO:0044744 protein targeting to nucleus
GO:0045066 regulatory T cell differentiation
GO:0045073 regulation of chemokine biosynthetic process
GO:0045075 regulation of interleukin-12 biosynthetic process
GO:0045080 positive regulation of chemokine biosynthetic process
GO:0045084 positive regulation of interleukin-12 biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045342 MHC class II biosynthetic process
GO:0045346 regulation of MHC class II biosynthetic process
GO:0045348 positive regulation of MHC class II biosynthetic process
GO:0045408 regulation of interleukin-6 biosynthetic process
GO:0045410 positive regulation of interleukin-6 biosynthetic process
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045589 regulation of regulatory T cell differentiation
GO:0045591 positive regulation of regulatory T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0045732 positive regulation of protein catabolic process
GO:0045785 positive regulation of cell adhesion
GO:0045786 negative regulation of cell cycle
GO:0045830 positive regulation of isotype switching
GO:0045834 positive regulation of lipid metabolic process
GO:0045862 positive regulation of proteolysis
GO:0045911 positive regulation of DNA recombination
GO:0045921 positive regulation of exocytosis
GO:0045926 negative regulation of growth
GO:0045940 positive regulation of steroid metabolic process
GO:0046136 positive regulation of vitamin metabolic process
GO:0046165 alcohol biosynthetic process
GO:0046209 nitric oxide metabolic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046889 positive regulation of lipid biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0048291 isotype switching to IgG isotypes
GO:0048302 regulation of isotype switching to IgG isotypes
GO:0048304 positive regulation of isotype switching to IgG isotypes
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0048732 gland development
GO:0048872 homeostasis of number of cells
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050701 interleukin-1 secretion
GO:0050702 interleukin-1 beta secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050706 regulation of interleukin-1 beta secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050718 positive regulation of interleukin-1 beta secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050755 chemokine metabolic process
GO:0050769 positive regulation of neurogenesis
GO:0050796 regulation of insulin secretion
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050810 regulation of steroid biosynthetic process
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0050900 leukocyte migration
GO:0050954 sensory perception of mechanical stimulus
GO:0051043 regulation of membrane protein ectodomain proteolysis
GO:0051044 positive regulation of membrane protein ectodomain proteolysis
GO:0051047 positive regulation of secretion
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051341 regulation of oxidoreductase activity
GO:0051353 positive regulation of oxidoreductase activity
GO:0051607 defense response to virus
GO:0051709 regulation of killing of cells of other organism
GO:0051712 positive regulation of killing of cells of other organism
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0051969 regulation of transmission of nerve impulse
GO:0060047 heart contraction
GO:0060251 regulation of glial cell proliferation
GO:0060326 cell chemotaxis
GO:0060330 regulation of response to interferon-gamma
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060334 regulation of interferon-gamma-mediated signaling pathway
GO:0060549 regulation of fructose 1,6-bisphosphate 1-phosphatase activity
GO:0060550 positive regulation of fructose 1,6-bisphosphate 1-phosphatase activity
GO:0060551 regulation of fructose 1,6-bisphosphate metabolic process
GO:0060552 positive regulation of fructose 1,6-bisphosphate metabolic process
GO:0060556 regulation of vitamin D biosynthetic process
GO:0060557 positive regulation of vitamin D biosynthetic process
GO:0060558 regulation of calcidiol 1-monooxygenase activity
GO:0060559 positive regulation of calcidiol 1-monooxygenase activity
GO:0060627 regulation of vesicle-mediated transport
GO:0060759 regulation of response to cytokine stimulus
GO:0061008 hepaticobiliary system development
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070673 response to interleukin-18
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071346 cellular response to interferon-gamma
GO:0071351 cellular response to interleukin-18
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0071621 granulocyte chemotaxis
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071887 leukocyte apoptotic process
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072012 glomerulus vasculature development
GO:0072109 glomerular mesangium development
GO:0072110 glomerular mesangial cell proliferation
GO:0072111 cell proliferation involved in kidney development
GO:0072124 regulation of glomerular mesangial cell proliferation
GO:0072125 negative regulation of glomerular mesangial cell proliferation
GO:0072535 tumor necrosis factor (ligand) superfamily member 11 production
GO:0072574 hepatocyte proliferation
GO:0072575 epithelial cell proliferation involved in liver morphogenesis
GO:0072576 liver morphogenesis
GO:0072593 reactive oxygen species metabolic process
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090003 regulation of establishment of protein localization to plasma membrane
GO:0090004 positive regulation of establishment of protein localization to plasma membrane
GO:0090087 regulation of peptide transport
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090150 establishment of protein localization to membrane
GO:0090183 regulation of kidney development
GO:0090185 negative regulation of kidney development
GO:0090192 regulation of glomerulus development
GO:0090194 negative regulation of glomerulus development
GO:0090276 regulation of peptide hormone secretion
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:0098900 regulation of action potential
GO:0098908 regulation of neuronal action potential
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901722 regulation of cell proliferation involved in kidney development
GO:1901723 negative regulation of cell proliferation involved in kidney development
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902593 single-organism nuclear import
GO:1902930 regulation of alcohol biosynthetic process
GO:1902932 positive regulation of alcohol biosynthetic process
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903076 regulation of protein localization to plasma membrane
GO:1903078 positive regulation of protein localization to plasma membrane
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1903522 regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1903541 regulation of exosomal secretion
GO:1903543 positive regulation of exosomal secretion
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903729 regulation of plasma membrane organization
GO:1903829 positive regulation of cellular protein localization
GO:1904375 regulation of protein localization to cell periphery
GO:1904377 positive regulation of protein localization to cell periphery
GO:1904407 positive regulation of nitric oxide metabolic process
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1904951 positive regulation of establishment of protein localization
GO:1990182 exosomal secretion
GO:1990266 neutrophil migration
GO:1990778 protein localization to cell periphery
GO:2000027 regulation of organ morphogenesis
GO:2000147 positive regulation of cell motility
GO:2000307 regulation of tumor necrosis factor (ligand) superfamily member 11 production
GO:2000309 positive regulation of tumor necrosis factor (ligand) superfamily member 11 production
GO:2000345 regulation of hepatocyte proliferation
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005133 interferon-gamma receptor binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044297 cell body
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa03050 Proteasome
hsa04060 Cytokine-cytokine receptor interaction
hsa04066 HIF-1 signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04380 Osteoclast differentiation
hsa04612 Antigen processing and presentation
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-877312: Regulation of IFNG signaling
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IFNG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IFNG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26740106Head and Neck Squamous Cell CarcinomaPromote immunity (T cell function)Similarly, knockdown of Sema4D in an HNSCC cell line resulted in a loss of MDSC function as shown by a decrease in the production of the immune-suppressive cytokines arginase-1, TGF-β, and IL-10 by MDSC, concomitant with recovery of T cell proliferation and IFN-γ production following stimulation of CD3/CD28.
26731475MelanomaPromote immunity (T cell function)The transcription factor BACH2 promotes tumor immunosuppression. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ.
26729864MelanomaPromote immunityVaccination with combination therapy uniquely restricted Th2-cytokine production by CD4 cells, relative to combination therapy alone, and enhanced IFNγ production by CD8 and CD4 cells.
26676749Head and Neck Squamous Cell CarcinomaPromote immunity (T cell function)Interferon gamma (IFNγ) and the epidermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to transmit tumor cell-mediated extrinsic or intrinsic signals, respectively. Collectively, our findings suggest a novel role for JAK2/STAT1 in EGFR-mediated immune evasion, and therapies targeting this signaling axis may be beneficial to block PD-L1 upregulation found in a large subset of HNC tumors.
26334519MelanomaPromote immunity (T cell function)In the tumor microenvironment, the combination therapy led to significantly downregulated levels of immunosuppressive factors, such as decreased numbers of myeloid-derived suppressor cells and regulatory T cells (Treg) cells and declined levels of interleukin-6 and chemokine ligand 2-in correlation with increased levels of proinflammatory cytokines, including tumor necrosis factor-α and IFN-γ as well as an elevation in the CD8(+) T-cell population.
26025380Melanoma; Lung CarcinomaPromote immunity (T cell function)Together, our study reveals a negative regulation by STAT3 signaling in T cells on cross-talk between myeloid cells and T cells through IFNγ/CXCR3/CXCL10, which is important for CD8(+) T cells homing to tumors.
26019274MelanomaPromote immunity (T cell function)Immunization in the presence of TPCS2a significantly increased activation of CD8 T cells compared with immunization without TPCS2a and as measured by CD8 T cell proliferation, production of proinflammatory IFN-γ, TNF-α, and IL-2, and prevention of tumor growth.
25814664ThymomaPromote immunity (T cell function)Taken together, DC-based immune response mediated by interferon-γ-induced IDO expression via GSK-3β activity not only regulates CD8(+) T-cell proliferation and cytotoxic T lymphocyte activity but also modulates OVA-pulsed DC vaccination against EG7 thymoma.
25765738MelanomaPromote immunity (infiltration)TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. CXCL10 has been implicated as a critical chemokine supporting T-cell infiltration into the TME.
22706089MelanomaPromote immunity (T cell function)Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function.
18381452Breast CarcinomaPromote immunity (T cell function)We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-gamma and can induce apoptosis of MMC in vitro.
18366058Cervical CarcinomaPromote immunity (T cell function)HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. The absence of killing correlated with limited T-cell degranulation against CaCxCL, but this was not due to antigen processing defects per se; CaCxCL could induce specific T-cell release of IFN-gamma and TNF-alpha, and CaCxCL could be killed in longer cytotoxicity assays (>20 hr).
18354038MelanomaPromote immunity (T cell function)Tumor-specific Th17-polarized cells eradicate large established melanoma. Contrary to the current view that Th1 cells are most important in tumor rejection, we found that Th17-polarized cells better mediated destruction of advanced B16 melanoma. Their therapeutic effect was critically dependent on interferon-gamma (IFN-gamma) production, whereas depletion of interleukin (IL)-17A and IL-23 had little impact.
18322182Uveal MelanomaInhibit immunity (T cell function); decrease the efficacy of immunotherapyModulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. Treatment with IFN-gamma boosted the MHC class I presentation machinery in uveal melanoma cells but suppressed their MHC class I-restricted CTL lysis.
18292536MelanomaPromote immunity (infiltration)Following implantation and treatment, expression of surface class I on tumor cells in vivo was increased in B16/OVA, but not in B16/OVA/DNM tumors, suggesting IFN-gamma acts directly on tumor cells to induce class I up-regulation. Thus, IFN-gamma is instrumental in creating a tumor microenvironment conducive for T cell infiltration and tumor cell target recognition.
16517708Head and Neck Squamous Cell CarcinomaPromote immunity (T cell function)First, lack of recognition of SCCHN cells by CTL is associated with marked down-regulation of the IFN-gamma-inducible APM components low-m.w. protein 2, TAP1, TAP2, and tapasin. Furthermore, the regulatory nature of the APM defects in SCCHN cells suggests that intralesional administration of IFN-gamma may have a beneficial effect on the clinical course of the disease and on T cell-based immunotherapy of SCCHN by restoring SCCHN cell recognition by CTL.
16397267Pancreatic carcinomaPromote immunity (T cell function)C57BL/6 EL-TGF-alpha x Trp53-/- mice, which develop spontaneous ductal pancreatic carcinoma, were generated. Intratumoral cytokine secretion of tumor necrosis factor-alpha, IFN-gamma, IL-6, and MCP-1 was lower in spontaneous tumors as well as the number of adoptively transferred tumor-specific T cells.
27407095Cervical carcinomaPromote immunityIntravaginal treatment of IL7-Fc, but not native IL7, induces upregulation of chemokines (CXCL10, CCL3, CCL4, and CCL5), cytokines (IFNγ, TNFα, IL6, and IL1β), and an adhesion molecule (VCAM-1) in the genital tract, leading to the recruitment of several leukocytes, including CD4, CD8, γδ T cells, and dendritic cells.
19378341Ovarian carcinomaPromote immunityUpon IFNgamma exposure, TAM purified from ovarian cancer ascites recover a M1 phenotype (IL-10(low), IL-12(high)), express high levels of CD86 and low levels of ILT3, enhance the proliferation of CD4(+) T lymphocytes and potentiate the cytotoxic properties of a MelanA-specific CD8(+) T cell clone. IFNgamma-treated TAM also secreted reduced levels of mediators promoting suppressive T cell accumulation (CCL18) and trophic for tumors (VEGF and MMP9).
19351841Gastrointestinal stromal tumorPromote immunityThe NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM.
28575677Melanoma; Head and Neck Squamous Cell CarcinomaPromote immunityshow that interferon gamma production by a subset of regulatory T?cells in the tumor microenvironment triggers Treg instability locally and restores anti-tumor immunity.
23530146LymphomaPromote immunity (T cell function)Previously, we found that adiponectin (APN) suppresses IL-2-induced NK cell activation by downregulating the expression of the IFN-γ-inducible TNF-related apoptosis-inducing ligand and Fas ligand. In this study, we assessed the role of APN in immune cell function, including NK cells, CTLs, and myeloid-derived suppressor cells, in EL4 and B16F10 tumor-bearing APN knockout (KO) mice. In APNKO mice, splenic NK cells showed enhanced cytotoxicity with and without IL-2 stimulation.
23481325NeuroblastomaPromote immunityVγ9Vδ2 T lymphocytes were attracted to NB-tumor masses of mice receiving ZOL where they actively modified tumor microenvironment by producing interferon-γ (IFN-γ), that in turn induced CXCL10 expression in NB cells. This study shows that human Vγ9Vδ2 T cells and ZOL in combination inhibit NB growth in vivo and may provide the rationale for a phase I clinical trial in patients with high-risk NB.
21292811Colon Carcinoma; Lymphoma; Breast Carcinoma; MelanomaPromote immunity (T cell function)We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma. The protective effect of CD73 deficiency on primary tumors was dependent on CD8(+) T cells and associated with an increased frequency of antigen-specific CD8(+) T cells in peripheral blood and tumors and increased antigen-specific IFN-γ production.
21282338LymphomaPromote immunityThe immunotherapeutic approach we developed utilizes a bifunctional fusion protein that binds tumor cells through NK (natural killer)-activating receptor NKG2D and that recruits and stimulates T cells through an anti-CD3 single-chain variable fragment (scFv-NKG2D). In vitro, this scFv-NKG2D fusion protein engaged both T cells and tumor cells, stimulating T cells to produce IFN-γ, and cytotoxicity against NKG2D ligand-positive tumor cells. In vivo, expression of scFv-NKG2D by NKG2D ligand-positive tumor cells reduced tumor burden and, in some cases, led to tumor-free survival.
21278794Breast CarcinomaPromote immunitySecretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-α and IFN-γ, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-α and IFN-γ, upregulates Fas expression, while blocking TNF-α and IFN-γ by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-κB has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-α and IFN-γ, transcriptionally controlled by NF-κB, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-κB-dependent autocrine loop, mediated by TNF-α and IFN-γ, responsible for expression of Fas on the surface of senescent cells, and for their killing.
21232138Breast CarcinomaPromote immunity (T cell function)This finding was correlated with an increased ability of tumor-draining lymph node cells and splenocytes from α-TEA-treated mice to secrete interferon (IFN)-γ in response to CD3 or to mediate a cytolytic response in a tumor-specific fashion, respectively.
21216894MelanomaPromote immunity (T cell function)Melanoma cell lysis by the CTL was increased by IFN-γ treatment due to preferential processing of the antigenic peptide by the immunoproteasome.
21207413MelanomaPromote immunity (T cell function)Tumor cells exposed to interferon-gamma (IFN-γ) were better recognized by the anti-MAGE-C2(42-50) CTL clone. Together, these results support the notion that the tumor regression of this patient was mediated by an antitumor response shaped by IFN-γ and dominated by CTL directed against peptides that are better produced by the immunoproteasome, such as the MAGE-C2 peptides.
21173239MelanomaPromote immunityClinical trials of CTLA-4-blocking antibodies to augment T-cell responses to malignant melanoma are at an advanced stage; however, little is known about the effects of CTLA-4 blockade on memory CD8(+) T-cell responses and the formation and maintenance of long-term CD8(+) T-cell memory. This is followed by an accumulation of memory cells that are capable of producing the effector cytokines IFN-γ and TNF-α.
21123824LeukemiaPromote immunity (T cell function)Herein we demonstrate that effector/memory CD4(+) T helper-1 (Th-1) lymphocytes, in addition to polarizing type-1 antitumor immune responses, impair tumor-induced CD4(+)CD25(+)FoxP3(+) regulatory T lymphocyte (Treg) immunosuppressive function in vitro and in vivo. Th-1 cells also inhibit the generation of FoxP3(+) Tregs from naive CD4(+)CD25(-)FoxP3(-) T cells by an interferon-γ-dependent mechanism.
19688743MelanomaPromote immunity (T cell function)Gadd45b, a signaling molecule highly up-regulated during Th1 type responses, is studied for its role in limiting tumor growth. Mouse B16 melanoma cells implanted into Gadd45b(-/-) mice grew faster than those in WT or Gadd45b(+/-) littermate controls. The defect of Gadd45b(-/-) mice in tumor immunosurveillance was attributed to the reduced expression of IFN-gamma, granzyme B, and CCR5 in Gadd45b(-/-) CD8(+) T cells at the tumor site.
19470694Ovarian CarcinomaPromote immunity (infiltration)Furthermore, through synergistic action between IL-17 and interferon-gamma, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor-infiltrating effector T cells. The levels of tumor-infiltrating Th17 cells and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome.
29090321Hepatocellular CarcinomaInhibit immunity (T cell function)In the present study, we asked whether TNF-α can promote the expression of B7-H1 induced by IFN-γ in HCC cells. We found that JAK/STAT1/IRF1 was the primary pathway responsible for induction of B7-H1 expression by IFN-γ in human HCC cell lines. TNF-α and IFN-γ synergistically induced the expression of B7-H1 in the HCC cells. Moreover, the mechanism of the synergy was that TNF-α enhanced IFN-γ signaling by upregulating the expression of IFN-γ receptors.
29034543Gastric CarcinomaInhibit immunity (T cell function)PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Our in?vitro findings showed that interferon gamma upregulated programmed death ligand-1 expression on solid tumor cells through the JAK-signal transducer and activator of transcription pathway, and impaired the cytotoxicity of tumor antigen-specific CTL against tumor cells.
16778218MelanomaPromote immunity (T cell function)In vivo depletion assay revealed that the antitumor effect of B16/IL-23 was mainly mediated by CD8+ T cells and IFN-gamma whereas that of B16/IL-27 mainly involved natural killer cells and was independent of IFN-gamma. We also found that antitumor effects of B16/IL-23 and B16/IL-27 were synergistically enhanced by treatment with IL-18 and IL-12, respectively. Our data support that IL-23 and IL-27 might play a role in future cytokine-based immunotherapy against poorly immunogenic tumors.
16751376Breast CarcinomaPromote immunity (T cell function)A single intratumoral injection of IL-12 and GM-CSF-encapsulated microspheres induces the complete regression of advanced spontaneous tumors in her-2/neu transgenic mice. Posttherapy molecular analysis of immune activation/suppression markers within the tumor microenvironment demonstrated a dramatic up-regulation of IFN-gamma and a concomitant down-regulation of Forkhead/winged-helix protein 3 (Foxp3), TGFbeta, and IL-10 expression.
16751375Lung CarcinomaPromote immunitySimilar antitumor and antimetastatic activities of IL-27 were also observed in IFN-gamma knockout mice. Immunohistochemical analyses with Abs against vascular endothelial growth factor and CD31 revealed that B16F10 + IL-27 cells markedly suppressed tumor-induced neovascularization in lung metastases. IL-27 was revealed to directly act on HUVECs and induce production of the antiangiogenic chemokines, IFN-gamma-inducible protein (IP-10) and monokine induced by IFN-gamma. Finally, augmented mRNA expression of IP-10 and monokine induced by IFN-gamma was detected at the s.c.
16680149Breast Carcinoma; Renal Cell Carcinoma; Colon Carcinoma; Lung CarcinomaPromote immunity (T cell function)Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8+ T cells capable of eradicating preestablished tumors. This combination therapy of three monoclonal antibodies (trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon (IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process.
16651448LeukemiaPromote immunity (T cell function)The cytokine interleukin (IL)-12 promotes CD8(+) T-cell cytotoxicity and, with IL-18, synergistically up-regulates IFN-gamma release. We have shown that culturing CD8(+) T cells ex vivo with IL-12 and IL-18 enhanced antitumor responses in vivo and in vitro using a model of C1498/ovalbumin, a murine acute myeloid leukemia cell line expressing the antigen ovalbumin. Maximal IFN-gamma release occurred after T-cell culture with IL-12 and IL-18. Tumor-specific in vitro cytotoxicity was enhanced by IL-12, unaffected by addition of IL-18, and abrogated in perforin-deficient T cells irrespective of cytokine exposure.
16585565Lung CarcinomaPromote immunity (T cell function)IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. Intraperitoneal administration of IFN-gamma stimulates the mobilization of NK cells into the circulation, but not their cell death or proliferation. Moreover, mobilization and migration of spleen NK cells in response to IFN-gamma treatment is dependent on the chemokine receptor CXCR3.
16540672Lung CarcinomaPromote immunityA single intratracheal administration of CCL21 gene-modified dendritic cells (DC-AdCCL21) led to a marked reduction in tumor burden with extensive mononuclear cell infiltration of the tumors. The reduction in tumor burden was accompanied by the enhanced elaboration of type 1 cytokines [IFN-gamma, interleukin (IL)-12, and granulocyte macrophage colony-stimulating factor] and antiangiogenic chemokines (CXCL9 and CXCL10) but a concomitant decrease in the immunosuppressive molecules (IL-10, transforming growth factor-beta, prostaglandin E(2)) in the tumor microenvironment. The DC-AdCCL21 therapy group revealed a significantly greater frequency of tumor-specific T cells releasing IFN-gamma compared with the controls.
27470968Gastrointestinal Stromal TumorInhibit immunity (T cell function)The inhibitory receptors PD-1, lymphocyte activation gene 3, and T-cell immunoglobulin mucin-3 were upregulated on tumor-infiltrating T cells compared with T cells from matched blood. In human GIST cell lines, treatment with imatinib abrogated the IFNγ-induced upregulation of PD-L1 via STAT1 inhibition. In KitV558Δ/+?mice, imatinib downregulated IFNγ-related genes and reduced PD-L1 expression on tumor cells. PD-1 and PD-L1 blockade in vivo each had no efficacy alone but enhanced the antitumor effects of imatinib by increasing T-cell effector function in the presence of KIT and IDO inhibition.
27463676MedulloblastomaInhibit immunity (T cell function)Interferon-γ (IFN-γ)-induced PD-L1 up-regulation on MB requires Cdk5, and disruption of Cdk5 expression in a mouse model of MB results in potent CD4(+) T cell-mediated tumor rejection. Loss of Cdk5 results in persistent expression of the PD-L1 transcriptional repressors, the interferon regulatory factors IRF2 and IRF2BP2, which likely leads to reduced PD-L1 expression on tumors. Our finding highlights a central role for Cdk5 in immune checkpoint regulation by tumor cells.
22333315Breast CarcinomaPromote immunity (T and NK cell function)In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes.
17363736Multiple Myeloma-IgGInhibit immunity (T cell function)We observed that B7-H1 was expressed in most MM plasma cells, but not cells isolated from monoclonal gammopathy of undetermined significance or healthy donors. This expression was increased or induced by IFN-gamma and Toll-like receptor (TLR) ligands in isolated MM plasma cells. Blocking the MEK/ERK pathway inhibited IFN-gamma-mediated and TLR-mediated expression of B7-H1. Inhibition of the MyD88 and TRAF6 adaptor proteins of the TLR pathway blocked not only B7-H1 expression induced by TLR ligands but also that mediated by IFN-gamma. IFN-gamma-induced STAT1 activation, via MEK/ERK and MyD88/TRAF6, and inhibition of STAT1 reduced B7-H1 expression. MM plasma cells stimulated with IFN-gamma or TLR ligands inhibited cytotoxic T lymphocytes (CTLs) generation and this immunosuppressive effect was inhibited by preincubation with an anti-B7-H1 antibody, the UO126 MEK inhibitor, or by transfection of a dominant-negative mutant of MyD88.
28428785Leukemia; Ewing Sarcoma; Lymphoma; NeuroblastomaInhibit immunity (NK cell function)We also observed a variable impact of IFNγ in NK cell-mediated lysis. For six of the cancer cell lines IFNγ resulted in increased resistance to NK cells, while for three of them it resulted in increased sensitivity. Modeling of the data suggests that the effect of IFNγ on NK cell-mediated tumor lysis is mostly dependent on changes in MHC-class I and ICAM-1 expression. For three of the cell lines with increased resistance, we observed higher upregulation of MHC-class I than ICAM-1.
28428785Neuroblastoma; GlioblastomaPromote immunity (NK cell function)Modeling of the data suggests that the effect of IFNγ on NK cell-mediated tumor lysis is mostly dependent on changes in MHC-class I and ICAM-1 expression. For the cell lines with increased sensitivity after IFNγ treatment, we observed upregulation of ICAM-1 exceeding MHC-class I upregulation. ICAM-1 upregulation resulted in increased conjugate formation between the NK cells and tumor cells, which can contribute to the increased sensitivity observed.
24789737Lung CarcinomaPromote immunityOverexpression of miR-301a in DCs suppressed IL-12 secretion, decreased IFN-γ release from antigen-specific cytotoxic T cells, and shifted antigen-specific T helper cytokine profile away from IFN-γ towards IL-13 and IL-17A-secreting T cells.
20889921MelanomaInhibit immunity (T cell function)Surprisingly, CTL tumor recognition and antitumor effects decreased in the presence of interferon γ (IFNγ), a cytokine that can provide therapeutic benefit. Tumors exposed to IFNγ evade CTLs by inducing large amounts of noncognate major histocompatibility complex class I molecules, which limit T-cell activation and effector function.
19089914MelanomaInhibit immunity (NK cell function)Upon IFN-gamma treatment, expression of MICA, in some cases, also of ULBP2 decreased. Besides melanoma, this observation was made also for glioma cells. Down-regulation of NKG2DL surface expression was dependent on the cytokine dose and the duration of treatment, but was neither due to an intracellular retention of the molecules nor to an increased shedding of ligands from the tumor cell surface. Instead, quantitative RT-PCR revealed a decrease of MICA-specific mRNA levels upon IFN-gamma treatment and siRNA experiments pointed to an involvement of STAT-1 in this process. Importantly, IFN-gamma-treated MHC class I-negative melanoma cells were less susceptible to NKG2D-mediated NK cell cytotoxicity.
25046660LeukemiaPromote immunityInstead, we highlight a critical and nonredundant role for IFN-γ and TNF-α production by NK cells to enhance cross-presentation by DC using two different Ag models.
24919843Breast CarcinomaPromote immunityAn interferon γ and interleukin 2 enzyme-linked immunosorbent assay and a chromium-51 release assay were used to evaluate the antitumor immune response of CAR T cells in coculture with tumor cells.
29668066colon adenocarcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyConsequently, they release potent immunomodulatory mediators, including IFN-γ, TNF-α, and/or IL-17.
29662549lung adenocarcinomaPromote immunity (infiltration)TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-12 were analyzed by flow cytometry at the time of diagnosis and at 3 months after initiation of anti-PD-1 inhibition.
29661791melanomaPromote immunity (infiltration)IFN-γ production is largely restricted to T lymphocytes and natural killer (NK) cells and can ultimately lead to the generation of a polarized immune response composed of T helper (Th)1 CD4+ T cells and CD8+ cytolytic T cells.
29653690colon carcinomaPromote immunityHigh levels of INF-γ-secreting cells were identified in ELISpot and increased IFN-γ levels were found in cytokine ELISAs.
29630898Pancreatic ductal adenocarcinoma; melanoma; colon carcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyFlow cytometry analyses demonstrated that gut microbiome depletion led to significant increase in interferon gamma-producing T cells with corresponding decrease in interleukin 17A and interleukin 10-producing T cells.
29596910Recurrent Non-Small Cell Lung CarcinomaInhibit immunity (T cell function)We also found that interferon gamma (IFN-γ) extrinsically induced expression of PD-L2 through signal transducer and activator of transcription 1 signaling in NSCLC cells.
27793879Chronic Myeloid LeukemiaPromote immunityInterferon γ (IFN-γ) stimulation resulted in an upregulation of CIITA and MHC-II in CML stem/progenitor cells. Moreover, mixed lymphocyte reactions revealed that exposure of CD34+ CML cells to IFN-γ or RUX significantly enhanced proliferation of the responder CD4+CD69+ T cells.
24004819Breast CarcinomaPromote immunity (T cell function)PD-L1 was also decreased in IFNγ-treated COX-2KD mouse mammary cancer cells in vitro and, compared to control cells, growth of COX-2KD cells as orthotopic tumors in immune competent mice was markedly suppressed.
23986400MelanomaInhibit immunityMechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation.
23873689Ovarian CancinomaInhibit immunityIn turn, IFN-γ stimulates IL-18-binding protein production, which blocks IL-18 activity. However, its release is inducible both by IFN-γ stimulation in vitro and by xenotransplantation of EOC cells in immune-deficient mice, suggesting a role for the microenvironment.
23851682Lung Adenocarcinoma; Non-Small Cell Lung CarcinomaPromote immunity (infiltration)Because mice bearing early NSCLC treated with anti-CD25 mAb exhibited increased tumor cell death associated with infiltration by CD8(+) T cells expressing elevated levels of granzyme A, granzyme B, perforin, and IFN-γ, we therefore evaluated carboplatin combination therapy resulting in a significantly extended survival beyond that observed with chemotherapy alone, indicating that Treg depletion in combination with cytotoxic therapy may be beneficial as a treatment strategy for advanced NSCLC.
23843024Breast CarcinomaPromote immunity (infiltration)Using MMTV-neu mice as an animal model for HER2-positive breast cancer, we observed enhanced tumor infiltration by IFN-γ-secreting T cells after treatment with doxorubicin and/or lapatinib. Antibody depletion experiments revealed a contribution of CD8? but not CD4? T cells to the antitumor effect of these drugs.
21540239B-Cell Non-Hodgkin LymphomaPromote immunity (T cell function)T-cell proliferation and IFN-γ secretion served as measures of T-cell activation.
21540234Renal Cell CarcinomaPromote immunity (T cell function); essential for immunotherapyNotably, the AZD8055/αCD40-induced antitumor response was abolished in IFN-γ(-/-) and CD40(-/-) mice, establishing the reliance of the combination therapy on host IFN-γ and CD40 expression.
21515097Colorectal CancinomaPromote immunityFurthermore, combined therapy potently generated specific cytotoxic IFN-γ-secreting CD4+ T cells able to eradicate established CRC tumours after adoptive transfer.
21482773Breast Carcinoma (ERBB-(+))Promote immunity (T cell function); essential for immunotherapyWe report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL.
21455984Other Mammary Carcinoma of MousePromote immunityTLR4 deficient mice developed more tumors relative to the WT mice. T cells of TLR4 deficient mice produced elevated levels of IL-17 and lower levels of IFN-γ relative to WT mice. IL-12 secreted by CD11c(+) cells was higher in WT mice, whereas greater amounts of IL-23 were produced by CD11c(+) cells from TLR4 deficient mice.
21447719Renal Cell Carcinoma; MelanomaPromote immunityIFN-γ and interferon-inducible protein-10 (IP-10) were elevated in all patients, indicating activation of cell-mediated immune response; this was attenuated at subsequent cycles.
21310823LeukemiaPromote immunity (T cell function)Increased HLA-DR and IFN-γ expression was observed for CD4(+) T cells stimulated with CLIP(-) leukemic blasts, in contrast to CLIP(+) leukemic blasts, which indicated an activation and polarization of the CD4(+) T cells toward T-helper 1 cells. In addition, CLIP(-) leukemic blasts induced greater outgrowth of effector memory CD4(+) T cells (with HLA-DR-restricted T-cell receptor Vβ repertoires) that were associated with better leukemia-specific reactivity than with CLIP(+) leukemic blasts.
20008791Acute Myeloid LeukemiaPromote immunityBidirectional signaling following CD137-CD137L interaction induced the release of the immunomodulatory cytokines interleukin-10 and TNF by AML cells and directly diminished granule mobilization, cytotoxicity, and interferon-gamma production of human NK cells, which was restored by blocking CD137.
29336814Pancreatic CarcinomaPromote immunityCoculture supernatants of conditioned medium displayed significant inhibition of interferon γ and granzyme B secretion, both of which are crucial for induction of target cell cytotoxicity.
29308312Metastatic MelanomaPromote immunityThe enhanced tumor destruction was accompanied with significantly increased tumor infiltration of CD4+ and CD8+ T cells as well as elevated IFN-γ in the tumor sites.
29301578B16 Malignant MelanomaPromote immunityNotch1 expression in B16 melanoma cells inhibited the infiltration of CD8+ cytotoxic T lymphocytes and .NK cells and reduced IFN-γ release in tumor tissue
29124314MelanomaPromote immunityMoreover, this concurrent depletion restored production of inflammatory cytokine IFN-γ and enhanced tumor-specific CTL response, which subsequently resulted in the reduction of tumor growth and the improved survival rate of vaccinated mice.
29150430MelanomaInhibit immunityInterferon-γ (IFNG) signaling activated the expression of the human CTLA4 gene in a melanocyte and melanoma cell-specific manner. Mechanistically, IFNG activated CTLA4 expression through JAK1/2-dependent phosphorylation of STAT1, which bound a specific gamma-activated sequence site on the CTLA4 promoter, thereby licensing CBP/p300-mediated histone acetylation and local chromatin opening.
24477907MelanomaEssential for immunotherapyAlthough successful DC immunotherapy required IFN-γ, perforin expression was dispensable.
21712396MelanomaPromote immunityIFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. Lung metastases of IFN-γRDN B16 was also increased in NK cell-depleted or IFN-γ(-/-) mice, suggesting that the IFN-γ response of host cells was required in the NK cell and IFN-γ-mediated antimetastatic effect. Our results demonstrate that IFN-γ production from lung resident NK cells is a key response in the natural resistance to the experimental lung metastasis of NK cell-resistant tumor cells.
21632715Lung CarcinomaPromote immunityDichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. Importantly, the initial recruitment and activation of iDC as well as the subsequent switch to tolerogenic activity were both driven by IFN-γ, revealing the dichotomous role of this cytokine in regulating IL-12-mediated antitumor T cell immunity.
20372104Primary Cutaneous LymphomaPromote immunityTwenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-gamma] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type. Repeated intralesional therapy using TG1042 consistently results in local tumor regressions in about half of treated patients and one-third of patients also in regressions in noninjected distant lesions, likely reflecting the systemic immune activation after intralesional therapy.
18922917Lymphoma; MelanomaPromote immunity (infiltration)Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Exogenous application of IFN-gamma in the tumor augmented levels of ligands of the chemokine receptor CXCR3, increased NK cell accumulation, and prolonged survival. Our results identify IFN-gamma and the expression of CXCR3 on NK cells as prerequisites for NK cell infiltration into tumors.
18768900Brain NeoplasmPromote immunityFinally, we show that production of IFN-gamma, but not perforin or TNF-alpha, by the donor lymphocytes is critical for control of autochthonous brain tumors.
16227989MelanomaPromote immunityIntratumoral release of IFN-gamma had two crucial effects: inhibition of tumor angiogenesis and upregulation of major histocompatibility complex (MHC) class I expression on tumor cells.
16186187Rectal Carcinoma; FibrosarcomaEssential for immunotherapyA single administration of agonistic anti-GITR monoclonal antibody (mAb) to tumor-bearing mice intravenously or directly into tumors provoked potent tumor-specific immunity and eradicated established tumors without eliciting overt autoimmune disease. The treatment led to tumor rejection in IFN-gamma-intact mice but not IFN-gamma-deficient mice.
16177085SarcomaPromote immunityIFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. In the present study, IFN-gamma was found to abrogate the generation/activation of CD4+ CD25+ regulatory T cells by immunization with SEREX-defined self-Ag. The important role of IFN-gamma produced by CD8+ T cells was shown in experiments demonstrating that CD4+ CD25+ T cells cotransferred with CD8+ T cells from IFN-gamma(-/-) mice, but not from wild-type BALB/c mice, became immunosuppressive and enhanced pulmonary metastasis when recipient animals were subsequently immunized with a SEREX-defined self-Ag and a CTL epitope.
25248763lymphomaPromote immunity (T cell function)Bone marrow chimeras revealed that IFNgammaR1 and Fas expression on immune cells was most critical for rejection, and SPLNX increased the frequency of activated macrophages (Mvarphi) within intraocular tumors in an IFNgamma- and Fas/FasL-dependent manner, suggesting an immune cell target of IFNgamma and Fas. As depletion of Mvarphis limited CD8 T cell-mediated rejection of intraocular tumors in SPLNX mice, our data support a model in which IFNgamma- and Fas/FasL-dependent activation of intratumoral Mvarphis by CD8(+) T cells promotes severe intraocular inflammation that indirectly eliminates intraocular tumors by inducing phthisis, and suggests that immunosuppressive mechanisms that maintain ocular IP interfere with the interaction between CD8(+) T cells and Mvarphis to limit the immunosurveillance of intraocular tumors.
25225903colorectal carcinomaPromote immunityWe have demonstrated a significant positive correlation between the expression of TNF and IFNG, reiterating the fact that both these cytokines act through TH1 pathways that are associated with immune deviation towards enhanced or suppressed tumour rejection based on their activity; the disease progression in the form of recurrent disease in CRC is likely to be due to the systemic immune suppression as represented by low IFNG expression in PBMC
25223833melanomaPromote immunityFliCi was recognizedmainly by TLR5, and the protective response depended on a functionalimmune system and particularly on IFN-γ.
25205103lymphomaPromote immunityIn addition, immunization of mice with an antigen mixed with HMGN1 augmented antigen-specific immune responses with greatly elevated production of IFNg, but not IL4 (25).
25205101melanomaPromote immunityHere, we report that ATP-mediated suppression of IFNgamma production by Th17 cells can be overcome by genetic ablation of CD73 or by using IL1beta instead of TGFbeta to program Th17 cells ex vivo. Th17 cells cultured in IL1beta were also highly polyfunctional, expressing high levels of effector molecules and exhibiting superior short-term control of melanoma in mice, despite reduced stem cell-like properties
25125657melanomaPromote immunity(T cell function)Here, we show that CCDC134 is differentially expressed on resting and activated immune cells and that it promotes CD8(+) T-cell activation, proliferation, and cytotoxicity by augmenting expression of the T-cell effector molecules IFNγ, TNFα, granzyme B, and perforin
25092892lymphomaPromote immunityOur data indicate that IFN-gamma beefs up macrophage innate response and cytotoxicity by downregulating miR-3473b to release PTEN from suppression, and then the increase of PTEN contributes to the full activation of IFN-gamma-primed macrophages.
23363816Head and Neck CarcinomaPromote immunityIn HNC cells, SHP2 depletion significantly upregulated expression of pSTAT1 and HLA class I APM components. Overexpression of SHP2 in nonmalignant keratinocytes inhibited IFN-gamma-mediated STAT1 phosphorylation, and SHP2 depletion in STAT1(-/-) tumor cells did not significantly induce IFN-gamma-mediated APM component expression, verifying STAT1 dependence of SHP2 activity
23341634fibrosarcoma; MelanomaPromote immunityComplete tumor rejection required IFNgamma-regulated Fas by the tumor stroma. Therefore, T(E) cells lacking IFNgamma or FasL cannot prevent progression of antigenic cancer because the tumor stroma escapes destruction if its Fas expression is down-regulated.
23333935Prostate Carcinoma; Colon CarcinomaPromote immunityAntibody neutralization assays show that IL-12 and IFN-γ are essential for the Flagrp170-elicited antitumor response, which also involves CD8(+) T cells and natural killer cells.
23319306Breast Carcinoma; MelanomaPromote immunityUpon reaching the bronchoalveolar space, aerosolized CpG-ODN activated a local immune response, as indicated by production of IL-12p40, IFN-gamma and IL-1beta and by recruitment and maturation of DC cells in bronchoalveolar lavage fluid of mice.
23315072MelanomaPromote immunityNevertheless, IFN-γ played a critical role by creating a microenvironment that promoted Tc17-mediated antitumor activity
23300177leukemiaPromote immunityWithin chronic lymphocytic leukemia proliferation centers in the lymph node, CD4(+)/PD-1(+) T lymphocytes were found to be in close contact with PD-L1(+) chronic lymphocytic leukemia cells. Lastly, functional experiments using recombinant soluble PD-L1 and blocking antibodies indicated that this axis contributes to the inhibition of IFN-γ production by CD8(+) T cells.
23292955Head and Neck Squamous Cell CarcinomaPromote immunityFurthermore, reduction of tumor cell CD47 increases phagocytosis of these cells by dendritic cells and leads to increased interferon gamma and granzyme production from mixed lymphocytes.
23288508Head and Neck Squamous Cell CarcinomaInhibit immunitySignificant levels of mRNA for IFN-gamma, a major cytokine inducer of PD-L1 expression, were found in HPV+ PD-L1(+) tumors.
23284053lymphomaPromote immunityWith respect to CD8(+) T cell responses, the coNS5A gene primed more potent IFN-γ-producing and lytic cytotoxic T cells in wt mice compared with NS5A-Tg mice.
23262246Hepatocellular CarcinomaPromote immunityMoreover, isolated HCC-infiltrating CD4(+)CD25(+) regulatory T cells (Treg cells) directly suppressed the cytotoxic function and IFN-γ secretion of γδ T cells in a TGFβ- and IL-10-dependent manner
23251005MelanomaPromote immunityWhen small metastatic melanoma foci were formed in the lungs, systemic administration of IL-12-conjugated HVJ-E significantly reduced the number of metastatic foci by inducing local production of IFN-γ in the lungs and generating large numbers of melanoma-specific CTLs.
23248262Gastric CarcinomaPromote immunityS100A8/A9 has been identified as a potential target to modulate antitumor immunity by reversing MDSC-mediated immunosuppression. The ability of MDSCs to suppress T lymphocyte response and the effect of S100A8/A9 and RAGE blocking were tested in vitro by (autologous) MLR. GC patients had significantly more MDSCs than healthy individuals. These MDSCs suppressed both T lymphocyte proliferation and IFN-gamma production and had high arginase-I expression.
23241877fibrosarcomaInhibit immunityTo our knowledge, these studies report for the first time that IFN-γ-mediated stress leads to the loss of specific chemokine expression by tumor cells, which in turn promotes tumor growth and evasion of the immune response.
23225218Hepatocellular CarcinomaPromote immunityHowever, in patients with advanced-stage HCC, NK cells were significantly decreased in number with impaired tumor necrosis factor alpha (TNF-alpha) and interferon-gamma (IFN-gamma) production.Further kinetic experiments revealed that soon after exposure to tumor-derived monocytes, NK cells underwent a rapid, transient activation, but then they became exhausted, and eventually died.
23204239MelanomaPromote immunityIFN-γ expression by TCR(hi) T cells was critical for upregulation of MHC-I on tumor cells and control of tumor growth.
21949133Lung CarcinomaPromote immunityIncreased apoptosis, the induction of cytokines (IFN-γ and IL-12) and chemokines (CXCL9 and CXCL10), and the elevation of leukocyte markers (CD11b, CD11c, CD4, and CD8) were detected at tumor sites in C3H/HeN mice but not in C3H/HeJ mice
21918960cervical squamous cell carcinomaPromote immunityE7(61-69) (CDSTLRLCV) and E7(67-76) (LCVQSTHVDI) induced significantly greater IFN-γ production as well as increased in vitro cytotoxicity against SiHa cells compared with those of other peptides and the negative control (P < .01), and the antitumor effects of these peptide-sensitized PBMCs were induced by CD8(+) CTLs.
21908738MyelomaPromote immunityMHC class I expression on myeloma cells and contact with T cells were required for CD8(+) T cell divisions and DP-T cell development. DP-T cells present in myeloma-infiltrated bones contained a higher proportion of cells expressing cytotoxic mediators IFN-gamma and/or perforin compared with single-positive CD8(+) T cells, acquired the capacity to degranulate as measured by CD107 expression, and contributed to an elevated perforin level seen in the myeloma-infiltrated bones.
21908576Merkel cell carcinomaPromote immunityIntracellular cytokine cytometry, IFN-γ enzyme-linked immunospot (ELISPOT) assay, and a novel HLA-A*2402-restricted MCPyV tetramer were used to identify and characterize T-cell responses against MCPyV oncoproteins in tumors and blood of MCC patients and control subjects. Although tetramer-positive CD8 T cells were detected in the blood of 2 of 5 HLA-matched MCC patients, these cells failed to produce IFN-g when challenged ex vivo with peptide.
21852386Breast CarcinomaInhibit immunityIn this study, we showed that breast tumor cell recognition by NK cells leads to their activation and IFN-g secretion, which in turn triggers CCL22 production by tumor cells through cooperation with monocyte-derived IL-1b and TNF-a.
21796616MelanomaPromote immunityThe production of multiple cytokines (IFNgamma, TNFalpha, IL-2) and upregulation of LAMP-1 (CD107a) by tumor (Melan-A/MART-1) specific T-cells was comparable to virus (EBV-BMLF1) specific CD8 T-cells. Furthermore, phosphorylation of STAT1, STAT5 and ERK1/2, and expression of CD3 zeta chain were similar in tumor- and virus-specific T-cells, demonstrating functional signaling pathways.
21792901renal cell carcinoma; melanoma; colon carcinomaPromote immunity (T cell function)The CD8 tumor-infiltrating T lymphocytes in 6-gingerol-treated mice strongly expressed IFN-γ, a marker of activation of cytotoxic T lymphocytes (CTL) CD107a and chemokine receptors that are expressed on T(H) 1 cells, such as CXCR3 and CCR5.
21784871Breast CarcinomaPromote immunityFurthermore, we showed that treatment with these NPs resulted in priming of the immune TME, characterized by increased IFN-gamma, p-STAT-1, GM-CSF, IL-2, IL-15, and IL-12b and reduced TGF-beta, IL-6, and IL-10 protein expression. In addition, we found significantly increased tumor infiltration by activated CD8(+) T cells, M1 macrophages, and dendritic cells.
21782419pancreatic carcinomaPromote immunityPSCs that overexpressed Galectin-1 induced apoptosis of CD4(+) T cells (p < 0.01) and CD8(+) T cells (p < 0.05) significantly, compared to normal PSCs. Knockdown of Galectin-1 in PSCs increased CD4(+) T cell (p < 0.01) and CD8(+) T cell viability (p < 0.05). Supernatants from T cells cocultured with PSCs that overexpressed Galectin-1 contained significantly increased levels of Th2 cytokines (IL-4 and IL-5, p < 0.01) and decreased Th1 cytokines (IL-2 and INF-gamma, p < 0.01).
17016559colon carcinomaInhibit immunityCD11b+IL-4Ralpha+ cells produced IL-13 and IFN-gamma and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment.
16998881Hepatocellular CarcinomaPromote immunityCytotoxic T lymphocyte (CTL) activity after WT p53 peptide-specific stimulation was assessed by analysis of granzyme B and interferon-gamma mRNA transcription, using a quantitative real-time polymerase chain reaction assay.
16998790MelanomaPromote immunityHere, we show that B16 melanoma cells actively modulate the interaction between DCs derived from bone marrow precursors and NK/LAK cells propagated from the spleen of C57BL/6 mice. DCs increased in a dose-dependent manner the ability of NK/LAK cells to kill melanoma cells and to produce cytokines. This activatory cross-talk entailed the production of IL-18 by DCs and of IFN-gamma by NK/LAK cells. Melanoma cells were not a passive target of NK activity; they regulated the outcome of the interaction between DCs and NK/LAK cells, inhibiting the in vitro production of cytokines as effectively as the genetic deletion of IL-18 or IFN-gamma.
16990769leukemiaPromote immunityAfter 21-day co-culture with DC pulsed with CD40L+ apoptotic BCP-ALL blasts, T cells presented with both effector and central memory phenotype, and showed high and specific cytotoxic activity against leukemic cells (average lysis = 77%), mostly mediated by CD8+ T cells. Noticeably, growth of CD4 T cells was maintained (45% of total cells), which actively produced Th1 cytokines (IFN-gamma, TNF-alpha, IL-2), but not IL-4, IL-5 and IL-10.
16982932lymphomaPromote immunityA single stimulation of CD8+ T cells from healthy virus carriers, and patients with HL with this adenoviral construct in combination with IL-2, was sufficient to reverse the functional T cell impairment and restored both IFN-gamma production and cytolytic function.
16982889mastocytomaPromote immunityHowever, these cells showed poor IFN-gamma and IL-2 production upon restimulation, consistent with T cell anergy and similar to the hyporesponsiveness induced by administration of soluble peptide Ag.
16980511Breast CarcinomaPromote immunityMechanical analysis showed that targeted expression of IP-10 in 4T1 tumor cells markedly enhanced the infiltration of tumor-specific T cells into the 4T1-IP-10 tumor. These tumor infiltrating T lymphocytes (TILs) recruited by IP-10 were potent cytolytic killers against 4T1 tumor cells and were able to proliferate and produce high levels of IFN-gamma in response to 4T1 cells. In vivo administration of IP-10-recruited TILs induced vigorous proliferation of these TILs in situ in the 4T1-IP-10 tumor but not in the 4T1-pcDNA3 and parental 4T1 tumors.
16953240MelanomaPromote immunityFinally, we show that in situ tumour ablation can be efficiently combined with immune modulation by anti-CTLA-4 antibodies or regulatory T-cell depletion. These combination treatments protected mice from the outgrowth of tumour challenges, and led to in vivo enhancement of tumour-specific T-cell numbers, which produced more IFN-gamma upon activation.
16951314PAN-CancerPromote immunityExperiments with ERK-1/2 inhibitors demonstrated that bryostatin-1 induction of IFN- gamma and T-bet was ERK-dependent and IL-12-independent. Similar results were obtained from both normal donors and cancer patients. In summary, our results suggest that bryostatin-1-induced IFN-gamma expression is T-bet independent. They also suggest for the first time that IFN- gamma and T-bet can be induced in human DC through an ERK-dependent pathway. Bryostatin-1-induced IFN- gamma may play a crucial role in the initiation of the immune response, before specific recognition by T cells that could be beneficial in the treatment of cancer.
16920991leukemiaPromote immunityWe found that imatinib-treated CML-chronic phase patients showing a complete cytogenetic response had NKT cells capable of producing IFN-gamma, whereas NKT cells from patients who were only partially responsive to imatinib treatment did not produce IFN-gamma
16920987pancreatic carcinomaPromote immunityMedium conditioned by human pancreatic carcinoma cells inhibited iMo-DC proliferation, expression of costimulatory molecules (CD80 and CD40) and of HLA-DR, and functional activity as assessed by MLR and IL-12p70 production. iMo-DC generated from pancreatic carcinoma patients in advanced stages of the disease similarly showed decreased levels of HLA-DR expression and reduced ability to stimulate MLR in response to CD40L and IFN-gamma.
16899622colon carcinomaPromote immunityThe effect of CA4P was studied on tumor growth and on immune reactivity in vitro. RESULTS: Rats with preexisting tumor, immunized and treated with low-dose CA4P, had a significantly retarded tumor growth compared with rats receiving CA4P or immunization alone. Splenocytes from rats treated with this combination had a significantly enhanced antitumor immune response compared with splenocytes from control rats. Exposure of nonadherent splenocytes to CA4P in vitro did not enhance their proliferation. However, 3-hour pretreatment of adherent splenocytes with 0.3 microg/mL CA4P significantly enhanced proliferation and IFNgamma production of admixed nonadherent splenocytes, partly due to nitric oxide reduction.
16857809Carcinomatous AscitesPromote immunityCuNG treatment could resolve drug-resistant cancers through induction of apoptogenic cytokines, such as IFN-gamma and/or tumor necrosis factor-alpha, from splenic mononuclear cells or patient peripheral blood mononuclear cells and reduce the number of T regulatory marker-bearing cells while increase infiltration of IFN-gamma-producing T cells in the ascetic tumor site.
16844772MelanomaPromote immunityWe find that a recently described analogue, alpha-C-galactosylceramide (alpha-C-GalCer), more potently induces these innate and adaptive immune responses in mice. alpha-C-GalCer acts as a more effective trigger for IL-12 and IFN-gamma production, although it minimally elicits IL-4 and TNF-alpha release into the serum. Also, alpha-C-GalCer better mobilizes NKT and natural killer cells to resist B16 melanoma.
16818744colon carcinomaPromote immunityIn contrast, T cell IFN-gamma production was weak and CD8+ CTL responses were undetectable in mice with CT26 lung metastases and weak and transient following s.c. injection of CT26 cells, but were enhanced in the presence of anti-IL-10 and anti-TGF-beta. These findings suggest that tumor growth facilitates the induction or recruitment of CD4+ regulatory T cells that secrete IL-10 and TGF-beta and suppress effector CD8+ T cell responses.
16818683Head and Neck Squamous CarcinomaPromote immunityHere, we discuss evidence pointing to functional defects in the antigen-processing machinery as one mechanism underlying resistance of SCCHN cells to recognition and lysis by HLA class I antigen-restricted, tumor antigen-specific CTL. In addition, based on the restoration by IFN-gamma of SCCHN cell sensitivity to recognition by these CTL, we suggest strategies that may improve the clinical course of the disease by enhancing susceptibility of malignant cells to immune recognition.
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IFNG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IFNG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0190.967
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2010.802
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1760.788
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1590.877
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1940.894
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1110.946
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1670.165
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.1310.079
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1860.888
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.910.287
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0960.934
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682301.1981.8e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IFNG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IFNG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IFNG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIFNG
Nameinterferon, gamma
Aliases IFG; IFI; IFN-gamma; immune interferon; Interferon gamma
Chromosomal Location12q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IFNG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IFNG.
ID Name Drug Type Targets #Targets
DB01250OlsalazineSmall MoleculeIFNG, TPMT2
DB01296GlucosamineSmall MoleculeIFNG, MMP9, NFKB2, TNF4
DB05110VIR201BiotechIFNG1
DB05111FontolizumabBiotechIFNG1
DB05676ApremilastSmall MoleculeIFNG, IL2, NOS3, PDE4A, PDE4B, PDE4D, TNF7